Meru Networks

Dr. Bami Bastani is nominated as the Chairman of the Board of Directors of Sivers Semiconductors AB and is appointed Executive Chairman of Sivers Semiconductors Inc.

Retrieved on: 
Monday, February 12, 2024
Trident, Storm, Acquisition, GlobalFoundries, Senior, GSA, Committee, AI, Photonics, Wireless, Management, ICS, Communication, High-pass filter, Vice, Trident Microsystems, Heart, Telecommunications, RF, Sivers, Meru Networks

KISTA, Sweden, Feb. 12, 2024 /PRNewswire/ -- Sivers Semiconductors AB (STO: SIVE) today announced that its subsidiary, Sivers Semiconductors Inc., has appointed Dr. Bami Bastani as US Executive Chairman and has been nominated as the Chairman of the Board of Directors of Sivers Semiconductors AB.

Key Points: 
  • KISTA, Sweden, Feb. 12, 2024 /PRNewswire/ -- Sivers Semiconductors AB (STO: SIVE) today announced that its subsidiary, Sivers Semiconductors Inc., has appointed Dr. Bami Bastani as US Executive Chairman and has been nominated as the Chairman of the Board of Directors of Sivers Semiconductors AB.
  • Dr. Bastani joined Sivers' team as Strategic Advisor to the Board and the Management team in August 2023.
  • Prior to GlobalFoundries, Dr. Bastani held President, CEO, and Board member positions at Meru Networks, Trident Microsystems, and ANADIGICS.
  • The Nomination Committee sees Bami Bastani as an important resource in leading the Board of Directors as the Chairman.

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, Research, NSCLC, Biomarker, Pembrolizumab, Betta, Castration, HIV disease progression rates, Cetuximab, Partnership, NRG1, Cancer, Drug design, PSA, ESMO, Head, Prostate cancer, Abstract (summary), Pancreatic cancer, ORR, Douglas BTD Destroyer, Safety, PDAC, Patient, EAP, Eli Lilly and Company, Congress, ADT, Clinical trial, CT, Oncology, European Society for Medical Oncology, Toxic leukoencephalopathy, FDA, Lilly, CD3, Aes, HER2, Afatinib, RECIST, Lung cancer, MET, BLA, FTD, Mutation, EGFR, Pharmaceutical industry, Life insurance, Vaccine, Medical imaging, Telescope, Bank, Tutoring, Birth control, CRPC, HNSCC, Incyte, Meru Networks

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and provided a business update.

Key Points: 
  • In the planned trial, patients will be randomized to petosemtamab monotherapy or investigators’ choice of single agent chemotherapy or cetuximab.
  • Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
  • Initial safety data from this single arm cohort may support the initiation of a first-line registration trial with this combination.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.

Merus Announces Business Update Conference Call

Retrieved on: 
Monday, October 16, 2023
Memorial, Cetuximab, Abstract, NSCLC, ORR, HNSCC, Aes, BLA, PDAC, Memorial Sloan Kettering Cancer Center, EGFR, Safety, Lung cancer, Causality, Abstract (summary), Mutation, Interim, Principal, FDA, ESMO, RECIST, Webcast, Cancer, Neck, Head, European Society for Medical Oncology, Castration, Prostate cancer, EAP, NRG1, HER2, PD-1, Patient, Toxicity, Pharmaceutical industry, Cryptocurrency, Vaccine, Computer data storage, Platinum, Meru Networks

ET

Key Points: 
  • ET
    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that it will host a conference call to discuss a business update on Monday, October 16, 2023 at 7:30 a.m.
  • Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
  • Merus plans to report initial interim safety and efficacy data from this cohort in the first half of 2024.
  • Merus will hold a conference call and webcast for investors on October 16, 2023 at 7:30 a.m.

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
Friday, October 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

Retrieved on: 
Friday, October 13, 2023
MBA, NYSE, Colorectal cancer, RET, Safety, US Foods, Therapy, Oncolytics Biotech, Breakthrough therapy, Transfection, News, NRG1, Research, Eli Lilly and Company, Cancer, HIV disease progression rates, Gastrointestinal cancer, JD, MD Anderson Cancer Center, AstraZeneca, LLY, EDB, Spacecraft, TSX, Eye, Pyxis, Liver, Disease, System, FDA, RECIST, University, Pancreatic Cancer Action Network, Thorax, Immunotherapy, FTD, Extracellular matrix, Fusion, Neoplasm, Congress, GI, Incidence, ORR, MD, ONC, Meru Networks, Colon, AZN, Pancreatic cancer, Patient, BTC, Johns Hopkins University, Pharmaceutical industry, Durvalumab, Lancet

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Key Points: 
  • A lot of the main efforts in fighting this particular cancer are in line with the work of the Pancreatic Cancer Action Network (PanCAN).
  • They've been asking supporters from every state in the US to get in touch with Congress to boost federal funds for pancreatic cancer research.
  • Near the end of 2022, the FDA rewarded pelareorep with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • Out of the 13 patients checked, one had a complete response - something that doesn't happen often when treating pancreatic cancer.

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

Retrieved on: 
Tuesday, September 26, 2023
Gastrointestinal cancer, MDT, Breakthrough therapy, MBA, GH, Congress, Incidence, Helmy Eltoukhy, Patient, JAMA Network Open, Health, NYSE, Polyp, News, Disease, Oncolytics Biotech, Research, Attention, Biologics license application, MRD, ONC, Pancreatic Cancer Action Network, Data, JD, TSX, FDA, Lancet, GI, Pancreatic cancer, Human, CAD, NSCLC, Biomarker, NRG1, Colorectal cancer, CR, United States Congress, ORR, Clinical trial, FOLFIRINOX, ASCO, American Society of Clinical Oncology, Physician, EUS, Annual general meeting, Poster, Recurrence, Society, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Meru Networks, Nvidia, Medtronic

VANCOUVER, British Columbia, Sept. 26, 2023 /PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer among individuals younger than 55 years. Another study published in JAMA Network Open showed that early-onset cancer in people younger than 50 rose over the last decade, with gastrointestinal cancers seeing the fastest increase. This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now. Among the ongoing efforts that are drawing more attention in the pancreatic cancer space have been the developments coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Merus N.V. (NASDAQ: MRUS), Guardant Health, Inc. (NASDAQ: GH), Medtronic plc (NYSE: MDT), and even NVIDIA Corporation (NASDAQ: NVDA).

Key Points: 
  • This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Pelareorep delivered the company a big win near the end of 2022, when the FDA rewarded it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • "With a five-year survival rate of 12%, pancreatic cancer patients cannot afford to wait for new treatment options," said Julie Fleshman, JD, MBA, President and CEO of PanCAN.

Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases

Retrieved on: 
Tuesday, September 26, 2023
Gastrointestinal cancer, MDT, Breakthrough therapy, MBA, GH, Congress, Incidence, Helmy Eltoukhy, Patient, JAMA Network Open, Health, NYSE, Polyp, News, Disease, Oncolytics Biotech, Research, Attention, Biologics license application, MRD, ONC, Pancreatic Cancer Action Network, Data, JD, TSX, FDA, Lancet, GI, Pancreatic cancer, Human, CAD, NSCLC, Biomarker, NRG1, Colorectal cancer, CR, United States Congress, ORR, Clinical trial, FOLFIRINOX, ASCO, American Society of Clinical Oncology, Physician, EUS, Annual general meeting, Poster, Recurrence, Society, FTD, Breast cancer, Pharmaceutical industry, Medical imaging, Meru Networks, Nvidia, Medtronic

VANCOUVER, British Columbia, Sept. 26, 2023 /PRNewswire/ -- USA News Group - The seriousness of pancreatic cancer continues to grow, with increasing alarm since The Lancet published an analysis back in April 2023, showing a rising incidence of pancreatic cancer among individuals younger than 55 years. Another study published in JAMA Network Open showed that early-onset cancer in people younger than 50 rose over the last decade, with gastrointestinal cancers seeing the fastest increase. This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now. Among the ongoing efforts that are drawing more attention in the pancreatic cancer space have been the developments coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Merus N.V. (NASDAQ: MRUS), Guardant Health, Inc. (NASDAQ: GH), Medtronic plc (NYSE: MDT), and even NVIDIA Corporation (NASDAQ: NVDA).

Key Points: 
  • This has led to increased calls from pancreatic cancer organizations such as Pancreatic Cancer Action Network (PanCAN) for more action in the space, including advocating that the US Congress invest more in cancer research funding now.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Pelareorep delivered the company a big win near the end of 2022, when the FDA rewarded it with a Fast Track Designation (FTD) for treating advanced or metastatic pancreatic cancer.
  • "With a five-year survival rate of 12%, pancreatic cancer patients cannot afford to wait for new treatment options," said Julie Fleshman, JD, MBA, President and CEO of PanCAN.

Faron Pharmaceuticals Announces Board Changes

Retrieved on: 
Friday, September 22, 2023
Sensei, IPO, Drug development, Doctor of Philosophy, Cancer, CMO, Associate, Fårö, MD, Ageing, Pharmaceutical industry, Meru Networks, Uppsala University

Dr. Marie-Louise Fjällskog is a professional with extensive experience in the pharmaceutical and biopharmaceutical industry, particularly in the field of clinical oncology, translational research, and drug development.

Key Points: 
  • Dr. Marie-Louise Fjällskog is a professional with extensive experience in the pharmaceutical and biopharmaceutical industry, particularly in the field of clinical oncology, translational research, and drug development.
  • Her extensive expertise and leadership have also earned her a position on the board of Biovica International AB, a prominent biotech company in Sweden and in the US, respectively.
  • She is also on the board of Norwegian company Lytix Biopharma.
  • In January 2022, Dr. Fjällskog assumed the role of Chief Medical Officer at Faron where she lead Faron's clinical development programs, particularly the bexmarilimab program.

Merus to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, August 31, 2023
Citigroup, Conference, Meru Networks

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V .

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V .
  • (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:
    Citi's 2023 18th Annual BioPharma Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m.
  • ET
    The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website.
  • Archived presentations will also be available there for a limited time after the event.

Merus Announces Pricing of Public Offering of Common Shares

Retrieved on: 
Thursday, August 10, 2023
Attention, EEA, Communication, Floor, File, The 8th Floor, European Union (Withdrawal) Act 2018, Financial Conduct Authority, William Blair & Company, Telephone, Jefferies, BofA Securities, FSMA, Finance, Person, Cyprus Securities and Exchange Commission, Sale, Prospectus, Jefferies Group, S-3, Advertising, Investment, European Economic Area, Form, Madison Avenue, Security (finance), Guggenheim Partners, Life insurance, Property management, Reinsurance, EU, Share (finance), Meru Networks, L.L.C, Order

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an underwritten public offering of 6,818,182 common shares, at a public offering price of $22.00 per share (the “Offer Shares”).

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pricing of an underwritten public offering of 6,818,182 common shares, at a public offering price of $22.00 per share (the “Offer Shares”).
  • Merus also granted the underwriters a 30-day option to purchase up to an additional 1,022,727 common shares (the “Option Shares” and together with the Offer Shares, the “Shares”).
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters’ option to purchase the Option Shares, are expected to be approximately $150.0 million.
  • All of the shares in the offering are to be sold by Merus.